iBio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It focuses on the development of precision antibodies. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.

During the initial strike of the novel coronavirus, IBIO stock was a huge gamble. But with the stakes raised, the underlying biotech firm could turn out to be instrumental.

3 Reasons to Invest in, Not Trade iBio

Asset prices don't go up in a straight line, even if the company shows promise. Use the dip in IBIO stock now to get in at a favorable price.

Big Catalysts Are Just Around the Corner for iBio Stock

It appears iBio may have to settle for an assist in the race for a Covid-19 vaccine, but that gives investors little reason to buy IBIO stock. 
The post The Curtain Is Coming Down on IBIO appeared first on InvestorPlace.

The Curtain Is Coming Down on IBIO

Fears of a second coronavirus wave have Covid-19 focused biotech stocks surging again. So where does IBIO stock fit into the mix?

IBM Partnership and Rising Covid-19 Cases Are Lifting iBio Stock

Buying a stock because it could be part of the solution to coronavirus is a risky way to play an already volatile market. IBIO stock's weak financials make it all the more dependent on coronavirus drugs to deliver.

Right Now, iBio Stock Is Even More Risky Than You Might Have Thought

IBIO stock is on a bull run of epic proportions but there is little to suggest the biotech company can come up with a Covid-19 vaccine.
The post Why iBio Is an Excellent Pandemic Spec Play appeared first on InvestorPlace.

Why iBio Is an Excellent Pandemic Spec Play

AIM ImmunoTech Inc

Evoke Pharma

LiveXLive Media

Cheap stocks are effectively Wall Street's casino.

5 Cheap Stocks to Buy for $10 or Less

iBio stock is still a buy but it needs to land contracts with some major vaccine developers as we get closer to a Covid-19 vaccine
The post iBio Is in a Healthy Position With Covid-19 Vaccine Push appeared first on InvestorPlace.
More From InvestorPlace
		
					
				
					Why Everyone Is Investing in 5G All WRONG				
			
					
				
					America’s #1 Stock Picker Reveals His Next 1,000% Winner				
			
					
				
					Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company				
			
					
				
					Radical New Battery Could Dismantle Oil Markets

iBio Is in a Healthy Position With Covid-19 Vaccine Push

Shares of iBio Inc. IBIO, +3.87% rocketed 64% on heavy volume in premarket trading Friday, as the biotherapeutics and contract manufacturing company is set to be added to the Russell 2000 RUT, +1.69% and Russell 3000 RUA, +1.18% indexes.

IBio's stock rockets on heavy volume after Russell index inclusion

NEW YORK, June  26, 2020  (GLOBE NEWSWIRE) --  iBio, Inc.  (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics innovator and contract manufacturing organization, today announced that it will be added to the Russell 2000® and Russell 3000® indexes as part of this year's reconstitution. The additions will be made effective after the U.S. markets open on June 29, 2020.

iBio to be Added to the Russell 2000® and Russell 3000® Indexes

iBio Granted 18 Months of Free Access to IBM’s Clinical Trial Management System iBio Granted 18 Months of Free Access to IBM’s Clinical Trial Management System

iBio Selected by IBM Watson Health for the use of IBM Clinical Development Solution at No Cost to help Support clinical COVID-19 Vaccine Candidates

IBIO stock has drawn a good deal of interest of late. It's a speculative play with the potential to reward optimistic investors handsomely.

3 Pros, 3 Cons For Buying iBio Stock Right Now

The enthusiasm surrounding iBio stock is warranted since the company is yet to deliver a viable, commercially successful vaccine.
The post Coronavirus Hype Is Boosting iBio Shares to Unrealistic Levels appeared first on InvestorPlace.

Coronavirus Hype Is Boosting iBio Shares to Unrealistic Levels

As companies race to develop a Covid-19 vaccine, IBIO stock investors are likely paying too much for a potential manufacturing contract.
The post Early Shareholders Can Win If iBio Gets a Vaccine Contract appeared first on InvestorPlace.

Early Shareholders Can Win If iBio Gets a Vaccine Contract

Unlike other vaccine stocks, iBio has the tech it needs to scale up manufacturing of its candidate. That makes IBIO stock a buy here.

FastPharming Tech Makes iBio Stock a Buy

For investors in search of a novel coronavirus play, IBIO’s puny capitalization and continued one-trick pony press releases are fair warning and increasingly, so is the price chart
The post More Suspect PR and Now One More Reason to Walk Away From IBIO Stock appeared first on InvestorPlace.
More From InvestorPlace
		
					
				
					Why Everyone Is Investing in 5G All WRONG				
			
					
				
					Top Stock Picker Reveals His Next 1,000% Winner				
			
					
				
					The 1 Stock All Retirees Must Own				
			
					
				
					Look What America’s Richest Family Is Investing in Now

More Suspect PR and Now One More Reason to Walk Away From IBIO Stock

The price of iBio stock could double, if not triple in value on successful trials, and on the potential for FDA approval in the near term.
The post Why iBio Stock Could Triple on Successful Vaccine Trials appeared first on InvestorPlace.

Why iBio Stock Could Triple on Successful Vaccine Trials

Alpha Pro Tech

Co-Diagnostics

Carvana

Moderna

Shopify

Wayfair

These seven A- and B-rated names are some of the top risky stocks to buy for enterprising investors. Here's what you should know about each company.

7 Risky Stocks That Are Worth a Gamble

With the underlying vaccination business, IBIO stock could make you rich. At the same time, if things go awry, it could make you poor in a hurry.

It’s the Right Price but the Wrong Time to Invest in iBio

iBio's production facility could be used to manufacture a Covid-19 vaccine. It remains to be seen if IBIO stock will be a star or a bust.

For iBio, the Coronavirus Pandemic Was a Lucky Break

- IBIO-201, a subunit vaccine combining SARS-CoV-2 spike protein antigens with the Company’s proprietary LicKM booster technology, advances to preclinical immunization studies with the potential for rapid manufacturing scale-up in iBio’s FastPharming SystemTM -

iBio Announces Second COVID-19 Vaccine Program

IBIO stock is hardly alone as a direct play on the coronavirus vaccine industry. Nevertheless, the company separates itself from the muck with its proprietary ability to scale up solutions.

IBIO Will Continue to Power Higher on Its Superior Scalability

A bet on IBIO stock is a bet on its plant-based research and its FastPharming processes. IBIO is one of the hottest stocks for good reason.

Why iBio Stock Will Extend Its Bullish Streak

Every investor is betting on a vaccine. Unfortunately, the case for IBIO stock is simply too speculative, as its trials remain under wraps.

Slim Vaccine Chances Make iBio Stock Too Speculative Here

Arcturus Therapeutics

Dynavax Technologies

Inovio Pharmaceuticals

Novavax

Sorrento Therapeutics Inc

A race to develop a coronavirus vaccine is on, and these red-hot Covid-19 vaccine stocks are leading the way.

News for iBio Stock (IBIO)